source
- GSK to buy Nuvalent for $10.6B, gaining two lung-cancer drugs under FDA reviewGSK announced it will acquire Nuvalent, a biotech focused on lung cancer, in a transaction valued at about $10.6 billion. The deal gives GSK control of Nuvalent’s two experimental lung-cancer ther…
- Grace Science warns FDA bottleneck threatens ultra-rare gene therapy progressGrace Science, a biotech focused on ultra-rare diseases, has been developing a gene-therapy candidate that appeared close to regulatory approval. The company, co-founded by Nobel laureate Carolyn…